Milan, Italy – April 9, 2008 - Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announces today that data on the efficacy and safety of ralfinamide in an 8-week phase II trial in patients with different forms of peripheral neuropathic pain, will be presented during the American Academy of Neurology 60th Annual Meeting in the McCormick Place West Convention Center, Chicago, USA, 12-19 April 2008.
Poster 179, “Efficacy and Safety of Ralfinamide in an 8-Week, Randomized, Double-Blind, Placebo Controlled, International Trial in Patients with Neuropathic Pain (NP). Ralfinamide 001 Study Group”, will be presented during Poster Session III on Tuesday April 15, 2008, from 6pm to 7.30pm. Poster viewing will be from 4pm to 7.30pm.
The presentation will cover analyses on the results in subtypes of peripheral neuropathic pain.
About ralfinamide
Ralfinamide is a unique New Chemical Entity that is believed to mediate analgesic and anti-inflammatory effects through the modulation of ion channels implicated in pain and the inhibition of substance P.
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide for the treatment of Parkinson’s disease (PD) in conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer´s disease, and other therapeutic applications. Newron is conducting phase II trials with ralfinamide for the treatment of neuropathic and post surgical (dental) pain. In February 2008, Newron signed an agreement providing for the acquisition of 100% of the issued share capital of Hunter-Fleming, a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders. Newron is headquartered in Bresso, near, Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.
